GALLBLADDER CANCER MARKET SIZE AND SHARE ANALYSIS - GROWTH TRENDS AND FORECASTS (2023 - 2030)

Gallbladder Cancer Market, By Treatment Type (Surgery, Chemotherapy, Radiation Therapy, Immunotherapy, Targeted Therapy, and Others), By Cancer Type (Adenocarcinoma, Squamous cell carcinoma, Adenosquamous carcinoma, Small cell carcinoma, and Others), By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, and Others), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)

Recent Developments

On October 21, 2023, Regeneron Pharmaceuticals, Inc., a pharmaceutical company, announced the first presentation of key secondary endpoints for an investigational regimen of PD-1 inhibitor Libtayo (cemiplimab) as a neoadjuvant monotherapy in stage II to IV resectable Cutaneous Squamous Cell Carcinoma (CSCC)
In June 2023, Sirnaomics Ltd., a biopharmaceutical company, announced the advancement of STP705 for the treatment of Squamous Cell Carcinoma (isSCC) in situ into late-stage clinical development

Acquisition and partnerships

On August 1, 2023, Replimune Group, Inc., a clinical stage biotechnology company, and Incyte, a global biopharmaceutical company, announced a clinical trial collaboration and supply agreement to study RP1, Replimune Group, Inc. lead product candidate, in combination with INCB99280, Incyte’s small molecule oral PD-L1 inhibitor